Michael P. Chu

1.9k citations

66 papers · 1.2k indexed · h-index 21

Impact in

Hematology top 5%
- Multiple Myeloma Research and Treatments
Oncology top 5%
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers

Papers in

Hematology 30
- Multiple Myeloma Research and Treatments 24
Oncology 39
- CAR-T cell therapy research 12
- Peptidase Inhibition and Analysis 8
- Cancer Immunotherapy and Biomarkers 6

Co-authors: Michael B. Sawyer Sunita Ghosh Carole Chambers Randeep Sangha Andrew R. Belch Neil Chua Michael Smylie Suzanne Trudel
Journals: Blood (18 papers)Journal of Clinical Oncology (8 papers)Nature Medicine (2 papers)Clinical Colorectal Cancer (2 papers)Endocrinology (2 papers)
Partner nations: Canada United States Australia

In The Last Decade

Michael P. Chu

59 papers receiving 1.2k citations

Peers

Countries citing papers authored by Michael P. Chu

Since Specialization

Citations

This map shows the geographic impact of Michael P. Chu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael P. Chu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael P. Chu more than expected).

Fields of papers citing papers by Michael P. Chu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael P. Chu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael P. Chu. The network helps show where Michael P. Chu may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Michael P. Chu, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Michael P. Chu Line = papers co-authored together Michael P. Chu links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Tandem Autologous Stem Cell Transplantation Does Not Benefit High-Risk Myeloma Patients in the Maintenance Era: Real-World Results from The Canadian Myeloma Research Group Database Transplantation and Cellular Therapy ·Christopher P. Venner, Peter Duggan, Kevin Song, Donna Reece, Smriti Sharma, Jiandong Su, Víctor H. Jiménez‐Zepeda, Arleigh McCurdy, Martha Louzada, Hira Mian, Michaël Sébag, Darrell White, Julie Stakiw, Rami Kotb, A. J. Mayell, Tony Reiman, Dawn Wei Li. Lim, Michael P. Chu, Willian Estanley Cubías Gutierrez, Richard LeBlanc	2024	1
2	Incidence and Prevalence of Clinically Detected Smoldering Multiple Myeloma Among the General Population Blood ·Commune-Francin, Irwindeep Sandhu, Michael P. Chu, Kathryn N. Rankin, Arleigh McCurdy, A Shilin, Haiane Leite Dantas Coelho, Edward H. Koo, Geoffrey G. Whitney, Sabrina Albert, J. N. Fitch, Christopher R. McCudden, Alissa Visram	2024	0
3	ULK2 Is a Key Pro-Autophagy Protein That Contributes to the High Chemoresistance and Disease Relapse in FLT3-Mutated Acute Myeloid Leukemia International Journal of Molecular Sciences ·H. L., Moh Moh Kyi, Anna-Kate Goodall, Annisa Permata Tajudin, Michael P. Chu, Joseph Brandwein, Raymond Lai, Beatriz Castillo López	2024	3
4	Belantamab mafodotin, pomalidomide, and dexamethasone for triple class exposed/refractory relapsed multiple myeloma: a subgroup analysis of the ALGONQUIN trial Blood Cancer Journal ·Arleigh McCurdy, Donna Reece, Martha Louzada, Darrell White, Praful Yadav, Michael P. Chu, Rami Kotb, Hira Mian, Joey Chou, Jiandong Su, 世鹰, Dawn Wei Li. Lim, Suzanne Trudel	2024	2
5	Recommendations for the effective use of T-cell–redirecting therapies: a Canadian consensus statement Frontiers in Oncology ·Guido Lancman, Kevin Song, Darrell White, B U Park, Iman Sharif, M.T. Sadd, みやこ佐野, N. Kunimatsu, Rayan Kaedbey, Michael P. Chu	2024	2
6	MagnetisMM-3: Long-Term Update and Efficacy and Safety of Less Frequent Dosing of Elranatamab in Patients with Relapsed or Refractory Multiple Myeloma Blood ·H. Miles Prince, Nizar J. Bahlis, Paula Rodríguez‐Otero, Lionel Karlin, Luke P. Akard, Kaushikkumar D. Parmar, Michael P. Chu, Yuya Nagai, David H. Vesole, Anne Hickman, Sharon T. Sullivan, Eric Leip, Umberto Conte, Andrea Viqueira, Alexander M. Lesokhin	2024	5
7	Identification of disease-related aberrantly spliced transcripts in myeloma and strategies to target these alterations by RNA-based therapeutics Blood Cancer Journal ·Josephine Mago Moritz, Zuzana Chyra, Sigitas Verselis, Lindsay Parkinson, Ryutaro Okitsu, Ivane Abiatari, Srikanth Talluri, 고은입, Teru Hideshima, Michael P. Chu, Roman Hájek, David M. Dorfman, Linda M. Pilarski, Kenneth C. Anderson, Sophia Adamia	2023	3
8	Second Line Treatment and Outcomes of Patients with Multiple Myeloma: A Real World Multi-Institutional Report from the Canadian Myeloma Research Group (CMRG) Database Blood ·Arleigh McCurdy, Dawn Wei Li. Lim, Donna Reece, Christopher P. Venner, Darrell White, Jiandong Su, Michael P. Chu, Víctor H. Jiménez‐Zepeda, Kevin Song, Hira Mian, Michaël Sébag, Willian Estanley Cubías Gutierrez, Julie Stakiw, Tony Reiman, Rami Kotb, A. J. Mayell, Rayan Kaedbey, Martha Louzada, Richard LeBlanc	2023	1
9	Elranatamab in relapsed or refractory multiple myeloma: the MagnetisMM-1 phase 1 trial Nature Medicine ·Nizar J. Bahlis, Caitlin Costello, Noopur Raje, Moshe Levy, Bhagirathbhai Dholaria, Melhem Solh, Michael H. Tomasson, Michael A. Damore, Hanjing Liu, Cynthia Basu, Athanasia Skoura, Edward M. Chan, Suzanne Trudel, Andrzej Jakubowiak, Cristina Gasparetto, Michael P. Chu, Andrew Dalovisio, Michaël Sébag, Alexander M. Lesokhin	2023	76
10	An In Vitro Model for Acute Myeloid Leukemia Relapse Using the SORE6 Reporter International Journal of Molecular Sciences ·H. L., Anna-Kate Goodall, Annisa Permata Tajudin, Iyare Izevbaye, Michael P. Chu, Irwindeep Sandhu, Joseph Brandwein, Raymond Lai, Beatriz Castillo López	2023	4
11	Filgrastim-Induced Bone Pain Is More Prevalent and Severe during Stem Cell Mobilization Transplantation and Cellular Therapy ·Matthew Anaka, Veronika Anna Rojek-Wöckner, S. Turgeon, Anthea Peters, Ann Beirne, Christopher P. Venner, Irwindeep Sandhu, Michael P. Chu	2021	0
12	Open-Label, Phase 2 Study of Blinatumomab after First-Line Rituximab-Chemotherapy in Adults with Newly Diagnosed, High-Risk Diffuse Large B-Cell Lymphoma Blood ·Deborah A. Katz, Michael P. Chu, Kevin A. David, Catherine Thiéblemont, Nicholas Morley, Peter Suler, Yuqi Chen, James Kalabus, Joan Morris, Abraham Anderson, Ariel A. Avilion, Eva González‐Barca	2019	20
13	Constitutive Activation of STAT3 in Myeloma Cells Cultured in a Three-Dimensional, Reconstructed Bone Marrow Model Cancers ·Rutter Jeremy B., Ommoleila Molavi, Abdulraheem Alshareef, Magdalena Reiter, Qian Wang, Michael P. Chu, Christopher P. Venner, Irwindeep Sandhu, Anthea Peters, Afsaneh Lavasanifar, Raymond Lai	2018	20
14	The Survival Impact of Lenalidomide Maintenance Chemotherapy in Multiple Myeloma Patients Treated with Autologous Stem Cell Transplant and Bortezomib-Based Induction: An Analysis of Real World Data Blood ·Eric A. Buchanan, Irwindeep Sandhu, Michael P. Chu, Georges Bucyibaruta, Ismail Ismail, Andrew R. Belch, Linda M. Pilarski, 戸谷誠之, Christopher P. Venner	2017	2
15	The Evolving Impact on Survival Outcomes in Multiple Myeloma with Greater Access to Novel Treatment Regimens: Experience in a Real-World Cohort Blood ·أحمد جاسم حميد, Víctor H. Jiménez‐Zepeda, Nizar J. Bahlis, Paola Neri, Irwindeep Sandhu, Michael P. Chu, Ismail Ismail, Jason Tay, Peter Duggan, Andrew Belch, Georges Bucyibaruta, Linda M. Pilarski, 戸谷誠之, Christopher P. Venner	2017	1
16	SD-101, a Novel Class C CpG-Oligodeoxynucleotide (ODN) Toll-like Receptor 9 (TLR9) Agonist, Given with Low Dose Radiation for Untreated Low Grade B-Cell Lymphoma: Interim Results of a Phase 1/2 Trial Blood ·Ronald Levy, Patrick M. Reagan, Jonathan W. Friedberg, Nancy L. Bartlett, Leo I. Gordon, Abraham C.F. Leung, Joanna Peterkin, Biao Xing, Robert L. Coffman, Robert S. Janssen, Albert F. Candia, Michael S. Khodadoust, Matthew J. Frank, Steven Long, Debra K. Czerwinski, Michael P. Chu	2016	15
17	Concomitant Administration of Proton Pump Inhibitors and Capecitabine is Associated With Increased Recurrence Risk in Early Stage Colorectal Cancer Patients Clinical Colorectal Cancer ·Julia Sun, Kiyadh Burt, Christina Kim, Michael P. Chu, Grace Lai–Hung Wong, Sunita Ghosh, Chuangfeng Liu, Karen Mulder, Jennifer L. Spratlin, Carole Chambers, Michael B. Sawyer	2015	45
18	Gastric Acid Suppression Is Associated With Decreased Erlotinib Efficacy in Non–Small-Cell Lung Cancer Clinical Lung Cancer ·Michael P. Chu, Sunita Ghosh, Carole Chambers, Naveen S. Basappa, Charles Butts, Quincy S. Chu, David Fenton, Anil A. Joy, Randeep Sangha, Michael Smylie, Michael B. Sawyer	2014	80
19	Spatiotemporal dynamics of triglyceride storage in unilocular adipocytes Molecular Biology of the Cell ·Michael P. Chu, Harini Sampath, Burbano Rommel Mário Rodriguez, Christoph Kahl, Romel Somwar, Anda Cornea, Charles T. Roberts, Oleg Varlamov	2014	12
20	Putting the Pieces Together: Necrolytic Migratory Erythema and the Glucagonoma Syndrome Journal of General Internal Medicine ·M Veillet, Erin Gilbert, R. Samuel Hopkins, Helen Liu, Charles D. Lopez, Michael P. Chu, Jesús Gómez-Catalán, Brett C. Sheppard	2013	15

About Michael P. Chu

Michael P. Chu is a scholar working on Hematology, Oncology, Pathology and Forensic Medicine, Radiology, Nuclear Medicine and Imaging and Physiology, having authored 66 papers that have together received 1.2k indexed citations. Recurring topics across this work include Multiple Myeloma Research and Treatments (24 papers), CAR-T cell therapy research (12 papers), Protein Degradation and Inhibitors (10 papers), Peptidase Inhibition and Analysis (8 papers), Lymphoma Diagnosis and Treatment (8 papers), Monoclonal and Polyclonal Antibodies Research (7 papers), Cancer Immunotherapy and Biomarkers (6 papers) and Immunotherapy and Immune Responses (5 papers). The work is most often cited by research in Hematology (239 citations), Oncology (570 citations), Geriatrics and Gerontology (69 citations), Gastroenterology (49 citations) and Immunology (168 citations). Michael P. Chu has collaborated with scholars based in Canada, United States and Australia. Frequent co-authors include Michael B. Sawyer, Sunita Ghosh, Carole Chambers, Randeep Sangha, Andrew R. Belch, Neil Chua, Michael Smylie, Suzanne Trudel, Ian C. Paterson and Loree Larratt. Their work appears in journals such as Blood, Journal of Clinical Oncology, Nature Medicine, Clinical Colorectal Cancer and Endocrinology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact